Developer docs
API playgroundTry for free, no card

Search company profiles

Camena Bioscience

Full company profile

uuid00005wg

Namestring
Camena Bioscience
Legal namestring
Camena Bioscience
Websiteurl
camenabio.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Camena Bioscience is a Cambridge, UK-based synthetic biology company founded in 2016 that develops gSynth®, a TdT-free, multi-enzymatic DNA synthesis platform designed to overcome the accuracy, length, and complexity limitations of phosphoramidite chemistry. The platform is built on four integrated pillars: a proprietary enzyme mix for de novo synthesis and assembly, Addamers (high-purity reagent building blocks), the Cimban™ bioinformatics design algorithm, and green-chemistry synthesis reagents that eliminate organic solvents. Public performance claims include approximately 90% accuracy over 300 bp (versus approximately 30% for phosphoramidite), multi-kilobase per day throughput, and the ability to synthesise any sequence, any length, and any complexity without codon optimisation. The company holds multiple DNA synthesis patent applications filed since 2017 and registered trademarks on gSynth® and Cimban™.

Camena sells synthetic genes and licenses its platform primarily to top-tier pharmaceutical and biotechnology companies, with documented use cases spanning drug discovery, mRNA vaccine template DNA, cell and gene therapy development (including CAR-T, AAV, and CRISPR-Cas12a constructs), and antibody discovery. Revenue is generated through two channels: one-time sales of synthetic gene products and licensing/royalty arrangements for gSynth reagents and the Cimban algorithm, often under field-of-use restrictions. Distribution is exclusively direct enterprise — there is no self-serve channel — and engagement follows a three-step partnering funnel: initial single-service agreement, followed by field-of-use licensing, and culminating in a dedicated team transfer for on-site integration.

The company is headquartered at Chesterford Research Park, Cambridge, operates with approximately 25 employees, and is ISO 9001 and ISO 27001 certified. As of May 2024 it had secured a multi-million-pound revenue stream from leading gene synthesis consumers, closed a $10m Series A led by Mercia in July 2023, and received further Mercia funding in September 2025. The leadership team is anchored by co-founders Steve Harvey (CEO) and Derek Stemple (CSO), with Dr Nicola Thompson serving as Chair of the Board from May 2024.

Short descriptiontext

Camena Bioscience is a Cambridge-based synthetic biology company that develops gSynth®, a TdT-free enzymatic DNA synthesis platform, and sells synthetic genes and licenses the technology to top pharmaceutical, biotechnology, and advanced-therapy customers via direct enterprise sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enzymatic DNA synthesis, synthetic gene production, DNA synthesis platform, gene synthesis services, synthetic biology tools
Industry3 codes
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Synthetic DNA / Gene Synthesis
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Synthetic gene product sales
TypeOne Time License
Description

Camena sells synthetic genes directly to pharmaceutical and biotechnology companies. The company has secured multi-million-pound revenue streams and major commercial contracts with leading gene synthesis consumers. Sales are conducted via direct enterprise engagement and a structured partnering pipeline (service agreement → field-of-use licensing → on-site transfer).

camenabio.com
2Licensing and strategic partnerships
TypeLicensing Royalties
Description

The gSynth platform is offered under licensing agreements to strategic partners and internal cores. Licensees receive access to gSynth reagents and Cimban design algorithm, enabling them to use the technology within agreed fields of application. The platform includes a portfolio of technologies wholly owned and developed by Camena, offering full freedom to operate for licensees.

camenabio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1gSynth
Description

TdT-free enzymatic-based DNA synthesis platform for high-throughput production of synthetic genes of any sequence, length, or complexity.

camenabio.com
+1 more record
Core offering1 text field

Camena Bioscience develops and commercializes gSynth®, a proprietary TdT-free enzymatic DNA synthesis platform for the high-throughput production of synthetic genes of any sequence, any length, and any complexity. The company sells synthetic gene products directly to pharmaceutical and biotechnology customers and licenses the gSynth platform (reagents and Cimban design algorithm) to strategic partners under field-of-use agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ~90% accuracy over 300 bp vs ~30% for phosphoramidite synthesis
+3 more records
Product overview1 text field

Camena Bioscience offers a single unified product platform called gSynth®, which consists of four integrated pillars: a proprietary enzyme mix for de novo DNA synthesis and gene assembly, Addamers (reagent building blocks), the Cimban™ bioinformatics design algorithm, and green chemistry synthesis technology. These components work together to address challenges of accuracy, length, scale, and speed in synthetic DNA production, enabling synthesis of any sequence, any length, any complexity without the need for codon optimization or error-prone assembly processes.

Product and service2 records
1gSynth® DNA Synthesis Platform
CategoryDNA synthesis technology platform
Description

A TdT-free, multi-enzymatic DNA synthesis platform for the high-throughput production of synthetic genes of any sequence, any length, and any complexity. Precisely synthesises kilobases of DNA per day using a proprietary enzyme mix, Addamers, Cimban™ design algorithm, and green chemistry. Sold via direct enterprise sales and licensed to strategic partners under field-of-use agreements.

2Synthetic Gene Products
CategorySynthetic DNA products
Description

Custom synthetic DNA products manufactured using the gSynth platform and sold directly to pharmaceutical and biotechnology customers. Includes complex, multi-gene sequences, long constructs (over 300 bp at ~90% accuracy, with multi-kilobase capability per day), and gene-length DNA produced in a day without codon optimisation or error-prone assembly.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

Camena and Constructive Bio joined a collaborative project led by the Max-Planck Institute of Molecular Plant Physiology (MPI-MP) to develop synthetic chloroplast genomes. The project is backed by £9.1m funding from ARIA. Camena's DNA synthesis technology combines with Constructive Bio's large-scale DNA assembly toolkit to deliver highly complex constructs at scale for synthetic plant genomics.

2Max-Planck Institute of Molecular Plant Physiology (MPI-MP)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

MPI-MP leads the £9.1m ARIA-funded synthetic chloroplast genome project. Dr. Daniel Dunkelmann at MPI-MP leads the project, which also includes academics from University of Essex and UC Berkeley. The initiative aims to construct synthetic chloroplast genomes for optimising crop performance and developing plants as sustainable biofactories.

camenabio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

Academic partner in the ARIA-funded synthetic chloroplast genome project alongside MPI-MP, UC Berkeley, Camena Bioscience, and Constructive Bio. Represented by Pallavi Singh.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-08-14
Description

Academic partner in the ARIA-funded synthetic chloroplast genome project alongside MPI-MP, University of Essex, Camena Bioscience, and Constructive Bio. Represented by Patrick Shih.

5Dr Nicola Thompson
Strategic tierCoreTypeOthersAnnounced on2024-05-24
Description

Dr Nicola Thompson, an industry leader with experience developing and commercialising innovative technologies and therapeutic modalities, was appointed Chair of the Board. She was founding CEO of Amphista Therapeutics and held senior leadership roles at Roche and GSK. Her appointment forms part of the Company's growth plans to expand commercialisation of gSynth.

camenabio.com
6Lee Lindley
Strategic tierCoreTypeOthersAnnounced on2023-07-01
Description

Lee Lindley, a member of Mercia's investment team with nearly 10 years of corporate financing experience, joined Camena's Board as part of the Series A financing. He holds a BA in Natural Sciences from Cambridge and a Masters in Research Methods from Manchester.

camenabio.com
7Aditya Rajagopal
Strategic tierCoreTypeOthersAnnounced on2023-07-01
Description

Aditya Rajagopal, founder and CTO of ChromaCode, Inc. and co-founder and Executive Chairman of Esperto Medical, joined Camena's Board. He is also faculty at USC and Caltech, with BS, MS and PhD from Caltech.

camenabio.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Zyme Communications handles media relations and press release distribution for Camena Bioscience, including communications around funding announcements and board appointments. Contact: Katie Odgaard.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers6 records
TypeDirect peer
Description

Twist Bioscience is the leading commercial provider of synthetic DNA using a silicon-based DNA synthesis platform, directly competing with Camena in selling synthetic genes to pharma and biotech customers. It is the largest publicly traded pure-play in this space and sets the benchmark for scale, throughput, and pricing that Camena must match or differentiate against.

2DNA Script
TypeEmerging player
Description

DNA Script is developing enzymatic DNA synthesis using terminal deoxynucleotidyl transferase (TdT), directly addressing the same accuracy and length limitations Camena targets with gSynth. As a venture-backed enzymatic synthesis company, it is the closest architectural competitor despite Camena's TdT-free positioning.

TypeEmerging player
Description

Ansa Biotechnologies is developing a novel enzymatic approach to de novo DNA synthesis with a focus on long, complex sequences. It competes with Camena in the same emerging enzymatic synthesis category targeting gene-length constructs for therapeutic and synthetic biology applications.

TypeBroad incumbent
Description

GenScript is a major global life sciences services provider offering gene synthesis, protein production, and cell therapy services, directly overlapping with Camena's synthetic gene product sales to pharma and biotech customers. Its broader portfolio and established CDMO scale make it a key incumbent competitor.

TypeBroad incumbent
Description

IDT, now part of Danaher, is a leading provider of custom DNA and RNA oligonucleotides, gene synthesis, and genomic tools serving pharma, academic, and diagnostics customers. Its scale, customer reach, and Danaher distribution make it a broad incumbent in the synthetic DNA market where Camena competes.

TypeBroad incumbent
Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Camena Bioscience

Synthetic DNA / Gene Synthesiscamenabio.com

Camena Bioscience is a Cambridge-based synthetic biology company that develops gSynth®, a TdT-free enzymatic DNA synthesis platform, and sells synthetic genes and licenses the technology to top pharmaceutical, biotechnology, and advanced-therapy customers via direct enterprise sales.

What Camena Bioscience does

Camena Bioscience is a Cambridge, UK-based synthetic biology company founded in 2016 that develops gSynth®, a TdT-free, multi-enzymatic DNA synthesis platform designed to overcome the accuracy, length, and complexity limitations of phosphoramidite chemistry. The platform is built on four integrated pillars: a proprietary enzyme mix for de novo synthesis and assembly, Addamers (high-purity reagent building blocks), the Cimban™ bioinformatics design algorithm, and green-chemistry synthesis reagents that eliminate organic solvents. Public performance claims include approximately 90% accuracy over 300 bp (versus approximately 30% for phosphoramidite), multi-kilobase per day throughput, and the ability to synthesise any sequence, any length, and any complexity without codon optimisation. The company holds multiple DNA synthesis patent applications filed since 2017 and registered trademarks on gSynth® and Cimban™.

Camena sells synthetic genes and licenses its platform primarily to top-tier pharmaceutical and biotechnology companies, with documented use cases spanning drug discovery, mRNA vaccine template DNA, cell and gene therapy development (including CAR-T, AAV, and CRISPR-Cas12a constructs), and antibody discovery. Revenue is generated through two channels: one-time sales of synthetic gene products and licensing/royalty arrangements for gSynth reagents and the Cimban algorithm, often under field-of-use restrictions. Distribution is exclusively direct enterprise — there is no self-serve channel — and engagement follows a three-step partnering funnel: initial single-service agreement, followed by field-of-use licensing, and culminating in a dedicated team transfer for on-site integration.

The company is headquartered at Chesterford Research Park, Cambridge, operates with approximately 25 employees, and is ISO 9001 and ISO 27001 certified. As of May 2024 it had secured a multi-million-pound revenue stream from leading gene synthesis consumers, closed a $10m Series A led by Mercia in July 2023, and received further Mercia funding in September 2025. The leadership team is anchored by co-founders Steve Harvey (CEO) and Derek Stemple (CSO), with Dr Nicola Thompson serving as Chair of the Board from May 2024.

Camena Bioscience firmographics

Firmographics
Name
Camena Bioscience
Legal name
Camena Bioscience
Website
https://camenabio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Camena Bioscience is a Cambridge-based synthetic biology company that develops gSynth®, a TdT-free enzymatic DNA synthesis platform, and sells synthetic genes and licenses the technology to top pharmaceutical, biotechnology, and advanced-therapy customers via direct enterprise sales.
Ownership category
akta.pro rank

Camena Bioscience industry classification

Industry
Product category
Synthetic DNA / Gene Synthesis
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Enzymatic DNA synthesis
  • Synthetic gene production
  • DNA synthesis platform
  • Gene synthesis services
  • Synthetic biology tools

Where Camena Bioscience is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Camena Bioscience business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Synthetic gene product sales: Camena sells synthetic genes directly to pharmaceutical and biotechnology companies. The company has secured multi-million-pound revenue streams and major commercial contracts with leading gene synthesis consumers. Sales are conducted via direct enterprise engagement and a structured partnering pipeline (service agreement → field-of-use licensing → on-site transfer).
  2. Licensing and strategic partnerships: The gSynth platform is offered under licensing agreements to strategic partners and internal cores. Licensees receive access to gSynth reagents and Cimban design algorithm, enabling them to use the technology within agreed fields of application. The platform includes a portfolio of technologies wholly owned and developed by Camena, offering full freedom to operate for licensees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Camena Bioscience product offering

Product offering

Core offering

Camena Bioscience develops and commercializes gSynth®, a proprietary TdT-free enzymatic DNA synthesis platform for the high-throughput production of synthetic genes of any sequence, any length, and any complexity. The company sells synthetic gene products directly to pharmaceutical and biotechnology customers and licenses the gSynth platform (reagents and Cimban design algorithm) to strategic partners under field-of-use agreements.

Product overview

Camena Bioscience offers a single unified product platform called gSynth®, which consists of four integrated pillars: a proprietary enzyme mix for de novo DNA synthesis and gene assembly, Addamers (reagent building blocks), the Cimban™ bioinformatics design algorithm, and green chemistry synthesis technology. These components work together to address challenges of accuracy, length, scale, and speed in synthetic DNA production, enabling synthesis of any sequence, any length, any complexity without the need for codon optimization or error-prone assembly processes.

Differentiator

Problem solved

Functional benefit

Brands

  • gSynth: TdT-free enzymatic-based DNA synthesis platform for high-throughput production of synthetic genes of any sequence, length, or complexity.
  • Cimban

Products and services

  • gSynth® DNA Synthesis Platform A TdT-free, multi-enzymatic DNA synthesis platform for the high-throughput production of synthetic genes of any sequence, any length, and any complexity. Precisely synthesises kilobases of DNA per day using a proprietary enzyme mix, Addamers, Cimban™ design algorithm, and green chemistry. Sold via direct enterprise sales and licensed to strategic partners under field-of-use agreements.
  • Synthetic Gene Products Custom synthetic DNA products manufactured using the gSynth platform and sold directly to pharmaceutical and biotechnology customers. Includes complex, multi-gene sequences, long constructs (over 300 bp at ~90% accuracy, with multi-kilobase capability per day), and gene-length DNA produced in a day without codon optimisation or error-prone assembly.

Quantifiable outcome

  • ~90% accuracy over 300 bp vs ~30% for phosphoramidite synthesis
  • +3 more outcomes

Companies that use Camena Bioscience

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Camena Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Camena Bioscience partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Constructive BiocoreStrategic or Co-development Partner · 14 August 2025Camena and Constructive Bio joined a collaborative project led by the Max-Planck Institute of Molecular Plant Physiology (MPI-MP) to develop synthetic chloroplast genomes. The project is backed by £9.1m funding from ARIA. Camena's DNA synthesis technology combines with Constructive Bio's large-scale DNA assembly toolkit to deliver highly complex constructs at scale for synthetic plant genomics.
  • Max-Planck Institute of Molecular Plant Physiology (MPI-MP)coreStrategic or Co-development Partner · 14 August 2025MPI-MP leads the £9.1m ARIA-funded synthetic chloroplast genome project. Dr. Daniel Dunkelmann at MPI-MP leads the project, which also includes academics from University of Essex and UC Berkeley. The initiative aims to construct synthetic chloroplast genomes for optimising crop performance and developing plants as sustainable biofactories.
  • University of EssexminorStrategic or Co-development Partner · 14 August 2025Academic partner in the ARIA-funded synthetic chloroplast genome project alongside MPI-MP, UC Berkeley, Camena Bioscience, and Constructive Bio. Represented by Pallavi Singh.
  • UC BerkeleyminorStrategic or Co-development Partner · 14 August 2025Academic partner in the ARIA-funded synthetic chloroplast genome project alongside MPI-MP, University of Essex, Camena Bioscience, and Constructive Bio. Represented by Patrick Shih.
  • Dr Nicola ThompsoncoreOthers · 24 May 2024Dr Nicola Thompson, an industry leader with experience developing and commercialising innovative technologies and therapeutic modalities, was appointed Chair of the Board. She was founding CEO of Amphista Therapeutics and held senior leadership roles at Roche and GSK. Her appointment forms part of the Company's growth plans to expand commercialisation of gSynth.
  • Lee LindleycoreOthers · 1 July 2023Lee Lindley, a member of Mercia's investment team with nearly 10 years of corporate financing experience, joined Camena's Board as part of the Series A financing. He holds a BA in Natural Sciences from Cambridge and a Masters in Research Methods from Manchester.
  • Aditya RajagopalcoreOthers · 1 July 2023Aditya Rajagopal, founder and CTO of ChromaCode, Inc. and co-founder and Executive Chairman of Esperto Medical, joined Camena's Board. He is also faculty at USC and Caltech, with BS, MS and PhD from Caltech.
  • Zyme CommunicationsminorGTM or Marketing PartnerZyme Communications handles media relations and press release distribution for Camena Bioscience, including communications around funding announcements and board appointments. Contact: Katie Odgaard.

Scale indicators7 records

Recent moves8 records

Expansion highlights3 records

Camena Bioscience competitors and assessment

Company assessment

Direct peers

  • Twist Bioscience: Twist Bioscience is the leading commercial provider of synthetic DNA using a silicon-based DNA synthesis platform, directly competing with Camena in selling synthetic genes to pharma and biotech customers. It is the largest publicly traded pure-play in this space and sets the benchmark for scale, throughput, and pricing that Camena must match or differentiate against.

Emerging players

  • DNA Script: DNA Script is developing enzymatic DNA synthesis using terminal deoxynucleotidyl transferase (TdT), directly addressing the same accuracy and length limitations Camena targets with gSynth. As a venture-backed enzymatic synthesis company, it is the closest architectural competitor despite Camena's TdT-free positioning.
  • Ansa Biotechnologies: Ansa Biotechnologies is developing a novel enzymatic approach to de novo DNA synthesis with a focus on long, complex sequences. It competes with Camena in the same emerging enzymatic synthesis category targeting gene-length constructs for therapeutic and synthetic biology applications.

Broad incumbents

  • GenScript: GenScript is a major global life sciences services provider offering gene synthesis, protein production, and cell therapy services, directly overlapping with Camena's synthetic gene product sales to pharma and biotech customers. Its broader portfolio and established CDMO scale make it a key incumbent competitor.
  • Integrated DNA Technologies (IDT): IDT, now part of Danaher, is a leading provider of custom DNA and RNA oligonucleotides, gene synthesis, and genomic tools serving pharma, academic, and diagnostics customers. Its scale, customer reach, and Danaher distribution make it a broad incumbent in the synthetic DNA market where Camena competes.
  • Eurofins Genomics:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Camena Bioscience social profiles

Digital presence

Camena Bioscience compliance and trust

Trust signal

Compliance2 records

Camena Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Camena Bioscience leadership team

Management profile

Number of profiles

Profiles14 records

Camena Bioscience funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Camena Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Camena Bioscience

What does Camena Bioscience do?

Camena Bioscience develops and commercializes gSynth®, a proprietary TdT-free enzymatic DNA synthesis platform for the high-throughput production of synthetic genes of any sequence, any length, and any complexity. The company sells synthetic gene products directly to pharmaceutical and biotechnology customers and licenses the gSynth platform (reagents and Cimban design algorithm) to strategic partners under field-of-use agreements.

Is Camena Bioscience a public or private company?

Camena Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Camena Bioscience founded?

Camena Bioscience was founded in 2016. It employs 11 to 50 people.

Where is Camena Bioscience based?

Camena Bioscience is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Camena Bioscience make money?

Two revenue lines are on record. Synthetic gene product sales are the primary driver. The others are licensing and strategic partnerships.

Who are Camena Bioscience's main competitors?

Twist Bioscience is listed as a direct peer. Emerging players are DNA Script and Ansa Biotechnologies. Broad incumbents are GenScript, Integrated DNA Technologies (IDT) and Eurofins Genomics.

Does Camena Bioscience have an API?

No public API is recorded for Camena Bioscience.

What industry is Camena Bioscience in?

Camena Bioscience's product category is Synthetic DNA / Gene Synthesis. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageCamena Bioscience Appoints Gregory P. McGuinness as CEOCamena Bioscience announced the appointment of Gregory P. McGuinness as Chief Executive Officer to drive the company's strategic growth and commercialization of its gSynth® platform for AI-driven antibody discovery. McGuinness brings over 30 years of executive leadership experience in life sciences, diagnostics, and pharma, having previously led companies including Inanovate Inc. and TwiXimo Therapeutics Inc., and held senior roles at firms such as Genturi Inc. and DNA Electronics Ltd. The appointment positions Camena to scale operations globally as it seeks to establish its proprietary enzymatic DNA synthesis technology as the foundational engine for AI-based bio-innovation.Business Wire BlogCamena Bioscience Appoints Gregory P. McGuinness as CEOCamena Bioscience appointed Gregory P. McGuinness as CEO, bringing over 30 years of life sciences leadership. The appointment supports commercialisation of its gSynth platform for AI-driven antibody discovery and operational scaling. McGuinness previously served as CEO at Inanovate and TwiXimo Therapeutics.Business WeeklyCamena Bioscience raises fresh growth capitalCamena Bioscience raised fresh growth capital from existing investor Mercia Ventures and new sources, including John McCafferty. The company added Philip Nelson to its board, who leads Google's Accelerated Science team. It previously raised $10m in a Series A round in July 2023.Drug Discovery World (DDW)Synthetic biology collaboration to develop plant genomicsThe Max-Planck Institute of Molecular Plant Physiology is leading a collaborative project with Camena Bioscience and Constructive Bio to develop synthetic chloroplast genomes. Supported by £9.1 million in funding from the Advanced Research + Invention Agency, the initiative aims to overcome structural challenges in DNA synthesis to create plants capable of producing biofuels and pharmaceuticals.News-MedicalCamena Bioscience and Constructive Bio join synthetic biology collaboration to develop plant genomicsCamena Bioscience and Constructive Bio joined a Max-Planck Institute project to develop synthetic chloroplast genomes, using their DNA synthesis and assembly technologies. The initiative is backed by £9.1m from ARIA and aims to overcome structural challenges in chloroplast genome construction. The collaboration targets applications in crop optimization and biofuel production.Business Wire BlogCamena Bioscience and Constructive Bio Join Synthetic Biology Collaboration to Develop Plant GenomicsCamena Bioscience and Constructive Bio joined a project led by the Max-Planck Institute to develop synthetic chloroplast genomes, backed by £9.1m from ARIA. The collaboration aims to overcome technical barriers in synthesizing and assembling these complex genomes, which are 120–170 kilobases long and highly AT-rich.YahooCamena Bioscience and Constructive Bio Join Synthetic Biology Collaboration to Develop Plant GenomicsCamena Bioscience and Constructive Bio joined a Max-Planck Institute-led project to develop synthetic chloroplast genomes, backed by £9.1m from ARIA. The collaboration aims to overcome technical barriers in synthesizing and assembling these complex genomes, which are 120–170 kilobases long. The project targets applications in crop optimization and sustainable biofactories.CamenabioCamena Bioscience and Constructive Bio join synthetic biology collaboration to develop plant genomicsCamena Bioscience and Constructive Bio have joined a collaboration led by the Max-Planck Institute of Molecular Plant Physiology in Germany to develop synthetic chloroplast genomes, with the project receiving £9.1 million in funding from the Advanced Research + Invention Agency (ARIA). The initiative aims to overcome challenges in constructing these complex genomes, with the potential to improve crop performance and develop sustainable biofactories. The collaboration highlights the UK’s leadership in synthetic biology and aims to contribute to a bioeconomy projected to reach $30 trillion by 2050.Seed WorldMax Planck Institute Secures Major Funding for Pioneering Genome Optimization ProjectThe Max Planck Institute for Molecular Plant Physiology received £9.1 million from ARIA to support SyncSol, a project to design a universal chloroplast genome for plant breeding. The initiative aims to create crops that capture CO₂ or produce pharmaceuticals, with collaborators including Constructive Bio and Camena Bioscience.PR NewswireGlobal Enzymatic DNA Synthesis Market Report 2023-2028, Featuring Profiles of Telesis Bio, Twist Bioscience ,GenScript Biotech, Evonetix, Camena Bio, Molecular Assemblies, Touchlight and Kern SystemsThe global enzymatic DNA synthesis market was valued at US$253.42 million in 2022 and is projected to reach US$2.11 billion by 2028, a CAGR of 42.43%. DNA library synthesis held the largest segment share in 2022, driven by genomics research demand.